SIMAP

SIMAP will develop a simulation model of the cancer related MAP-kinase pathway, integrating and analyzing data from various types of resources, which may assist in the development of better cancer treatment.

The completion of the human genome gave hope for a new age of medical understanding, but 4-5 years later costs of drug development are still rising and the success rate has not improved. Drugs that have already hit the market are found to have major side effects not perceived in the past and are often given to patients without discrimination on their likeliness to respond.

Large scale methodologies that thrive in recent years, allowed the industry and academia to gather more information on RNAs and proteins. However, the understanding of the molecular and cellular processes is still lacking, not to mention the connection to the clinical outcome. In order to fully use this data, a comprehensive integration and modelling effort is needed. A systematic rational hypothesis-driven research approach connecting all those levels of information is a much needed computational tool. This is the main goal of SIMAP project.

The ultimate goal of SIMAP is to develop a comprehensive simulation biochemical model of EGFRMAP kinase pathway in connection to cancer clinical information. SIMAP will:

  • Incorporate low-level biochemical modelling of individual molecules;
  • Simulate the behaviour of the pathway;
  • Add genomic and proteomic data;
  • Incorporate individual patients’ responses; and
  • Analyze sub population of responses in the context of the biochemical behaviour and genotype data

For further information, please visit:
http://www.simap-project.org

Project co-ordinator:
Compugen Ltd.

Partners:

  • Aureus Pharma, (FR)
  • Compugen Ltd., (IL)
  • Consejo Superior de Investigaciones Científicas, (ES)
  • Halevi Dweck & Co.Arttic Israel Company Ltd., (IL)
  • Fundacio Institut De Recerca De L'Hospital Universitari Vall D'Hebron, (ES)
  • Fondazione IRCCS Istituto Nazionale Dei Tumori, (IT)
  • The Max-Planck Institute for Infection Biology, (DE)
  • The University of Glasgow, (UK)
  • The Weizmann Institute of Science, (IL)

Timetable: from 01/06 – to 12/08

Total cost: € 4.464.201

EC funding: € 3.126.662

Instrument: STREP

Project Identifier: IST-2004-027265

Source: FP6 eHealth Portfolio of Projects

Most Popular Now

How could Technology Better Support Pati…

The NHS exists to serve patients. But more could be done to make their experience a key focus when it comes to technology adoption, senior NHS delegates told a recent...

Artificial Intelligence: Unexpected Resu…

Artificial intelligence (AI) is on the rise. Until now, AI applications generally have "black box" character: How AI arrives at its results remains hidden. Prof. Dr. Jürgen Bajorath, a cheminformatics...

Printed Robots with Bones, Ligaments, an…

3D printing is advancing rapidly, and the range of materials that can be used has expanded considerably. While the technology was previously limited to fast-curing plastics, it has now been...

CGM Continues to Drive Digitization in H…

CompuGroup Medical SE & Co. KGaA (CGM), one of the world's leading e-health providers, successfully progressed the digitization in healthcare during the first three quarters in 2023. CGM supports physicians...

Orchestrating the New World of AI in Hea…

Orion Health's UK and Ireland Customer Conference 2023 focused on the future potential and immediate, practical application of AI to healthcare - and gave delegates a first look at the...

AI identifies Non-Smokers at High Risk f…

Using a routine chest X-ray image, an artificial intelligence (AI) tool can identify non-smokers who are at high risk for lung cancer, according to a study being presented next week...

Researchers Take New AI Approach to Anal…

Researchers at Karolinska Institutet and SciLifeLab in Sweden have combined artificial intelligence (AI) techniques used in satellite imaging and community ecology to interpret large amounts of data from tumour tissue...

Study Reveals Bias in AI Tools when Diag…

Machine learning algorithms designed to diagnose a common infection that affects women showed a diagnostic bias among ethnic groups, University of Florida researchers found. While artificial intelligence (AI) tools offer...

Medical AI Tool from UF, NVIDIA gets Hum…

A new artificial intelligence (AI) computer program created by researchers at the University of Florida and NVIDIA can generate doctors' notes so well that two physicians couldn't tell the difference...

Commission Opens Calls to Invest €42 Mil…

Today, the European Commission opened a new set of calls for proposals under the 2023-2024 Work Programmes of the Digital Europe Programme with a focus on advanced digital skills. The calls...

Bayer Championing Advancements in Radiol…

Bayer continues to advance its comprehensive Radiology portfolio with progress in the development pipeline of its investigational contrast agent as well as new innovations in the area of Artificial Intelligence...

MEDICA and COMPAMED: Medical Technology …

13 - 16 November 2023, Düsseldorf, Germany. After four days of business, MEDICA and COMPAMED in Düsseldorf delivered impressive confirmation that they are excellent platforms for the worldwide medical technology business...